WO2006088491A3 - Methods and compositions related to the modulation of intercellular junctions - Google Patents

Methods and compositions related to the modulation of intercellular junctions Download PDF

Info

Publication number
WO2006088491A3
WO2006088491A3 PCT/US2005/023266 US2005023266W WO2006088491A3 WO 2006088491 A3 WO2006088491 A3 WO 2006088491A3 US 2005023266 W US2005023266 W US 2005023266W WO 2006088491 A3 WO2006088491 A3 WO 2006088491A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
modulation
compositions
intercellular junctions
compositions related
Prior art date
Application number
PCT/US2005/023266
Other languages
French (fr)
Other versions
WO2006088491A2 (en
Inventor
Aarthi Chandrasekaran
Shiladitya Sengupta
David A Berry
Kristine Holley
Ganlin Zhao
Ram Sasisekharan
Original Assignee
Massachusetts Inst Technology
Aarthi Chandrasekaran
Shiladitya Sengupta
David A Berry
Kristine Holley
Ganlin Zhao
Ram Sasisekharan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology, Aarthi Chandrasekaran, Shiladitya Sengupta, David A Berry, Kristine Holley, Ganlin Zhao, Ram Sasisekharan filed Critical Massachusetts Inst Technology
Priority to CA002614068A priority Critical patent/CA2614068A1/en
Priority to EP05857486A priority patent/EP1768687A2/en
Publication of WO2006088491A2 publication Critical patent/WO2006088491A2/en
Publication of WO2006088491A3 publication Critical patent/WO2006088491A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to compositions and methods for the modulation of the permeability of the epithelial cell barrier complex. In particular, the invention provides compositions and methods for using polysaccharides, preferably glycosaminoglycans, and agents that modify cell surface glycosaminoglycans, preferably glycosaminoglycan-degrading enzymes to modulate intercellular junctions. The compositions and methods provided can be used to facilitate the delivery of biologically active molecules.
PCT/US2005/023266 2004-06-29 2005-06-29 Methods and compositions related to the modulation of intercellular junctions WO2006088491A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002614068A CA2614068A1 (en) 2004-06-29 2005-06-29 Methods and compositions related to the modulation of intercellular junctions
EP05857486A EP1768687A2 (en) 2004-06-29 2005-06-29 Methods and compositions related to the modulation of intercellular junctions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58443804P 2004-06-29 2004-06-29
US60/584,438 2004-06-29

Publications (2)

Publication Number Publication Date
WO2006088491A2 WO2006088491A2 (en) 2006-08-24
WO2006088491A3 true WO2006088491A3 (en) 2007-09-27

Family

ID=36688050

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/023266 WO2006088491A2 (en) 2004-06-29 2005-06-29 Methods and compositions related to the modulation of intercellular junctions

Country Status (4)

Country Link
US (1) US8529889B2 (en)
EP (1) EP1768687A2 (en)
CA (1) CA2614068A1 (en)
WO (1) WO2006088491A2 (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2341412A1 (en) * 1998-08-27 2000-03-09 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase i and ii
CA2643162C (en) * 1999-04-23 2018-01-02 Massachusetts Institute Of Technology Polymer identification, compositional analysis and sequencing, based on property comparison
WO2001066772A2 (en) 2000-03-08 2001-09-13 Massachusetts Institute Of Technology Heparinase iii and uses thereof
WO2002023190A2 (en) 2000-09-12 2002-03-21 Massachusetts Institute Of Technology Methods and products related to low molecular weight heparin
JP2004523479A (en) * 2000-10-18 2004-08-05 マサチューセッツ　インスティテュート　オブ　テクノロジー Methods and products for pulmonary delivery of polysaccharides
CA2484604C (en) * 2002-05-03 2011-08-02 Massachusetts Institute Of Technology .delta. 4,5 glycuronidase and uses thereof
WO2004055491A2 (en) 2002-05-20 2004-07-01 Massachusetts Institute Of Technology Novel method for sequence determination using nmr
JP4606712B2 (en) * 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー 2-O sulfatase compositions and related methods
US20050053664A1 (en) 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
CA2558984A1 (en) 2004-03-10 2005-09-22 Massachusetts Institute Of Technology Recombinant chondroitinase abc i and uses thereof
US20060057638A1 (en) * 2004-04-15 2006-03-16 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US20060127950A1 (en) 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US8529889B2 (en) 2004-06-29 2013-09-10 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
WO2006083328A2 (en) * 2004-09-15 2006-08-10 Massachusetts Institute Of Technology Biologically active surfaces and methods of their use
DE102008020113A1 (en) * 2008-04-23 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituted dihydropyrazolones and their use
WO2006105315A2 (en) * 2005-03-29 2006-10-05 Massachusetts Institute Of Technology Compositions and methods for regulating inflammatory responses
DE102005019712A1 (en) * 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone and its use
WO2007120478A2 (en) * 2006-04-03 2007-10-25 Massachusetts Institute Of Technology Glycomic patterns for the detection of disease
WO2008011216A2 (en) 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
DE102006050515A1 (en) * 2006-10-26 2008-04-30 Bayer Healthcare Ag New substituted dipyridiyl-dihydropyrazolone derivatives are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful to treat/prevent e.g. cardiovascular diseases, heart-circulation diseases, heart failure and anemia
DE102006050516A1 (en) 2006-10-26 2008-04-30 Bayer Healthcare Ag New pyrazol-3-one compounds are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful e.g. to treat and/or prophylaxis heart-circulation diseases, heart failure, anemia, chronic kidney diseases and renal failure
DE102006050513A1 (en) 2006-10-26 2008-04-30 Bayer Healthcare Ag New substituted dihydropyrazolone derivatives are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful to treat/prevent e.g. cardiovascular diseases, heart-circulation diseases, heart failure and anemia
WO2008060567A1 (en) * 2006-11-14 2008-05-22 Keryx Biopharmaceuticals, Inc. Glycosaminoglycan formulations in the treatment of vascular disease
US20080159964A1 (en) * 2006-12-29 2008-07-03 Enzon Pharmaceuticals, Inc. Use of adenosine deaminase for treating pulmonary disease
WO2008085912A1 (en) 2007-01-05 2008-07-17 Massachusetts Institute Of Technology Compositions of and methods of using sulfatases from flavobacterium heparinum
EP1978360A1 (en) * 2007-04-04 2008-10-08 UMC Utrecht Holding B.V. A method to improve barrier function of cell-cell junctions
WO2008124131A1 (en) * 2007-04-05 2008-10-16 The John Hopkins University Antifungal agents as neuroprotectants
RU2510274C2 (en) * 2008-05-07 2014-03-27 Дзе Реджентс Оф Дзе Юниверсити Оф Калифорния Therapeutic recovery and enhancement of ocular surface wetting
US8506944B2 (en) * 2008-05-07 2013-08-13 The Regents Of The University Of California Replenishment and enrichment of ocular surface lubrication
US8652506B2 (en) * 2008-06-05 2014-02-18 Boston Scientific Scimed, Inc. Bio-degradable block co-polymers for controlled release
WO2010109256A1 (en) * 2009-03-23 2010-09-30 Carlo Ghisalberti Enhanced treatment of joint and connective tissue damage
US20100257634A1 (en) * 2009-04-03 2010-10-07 Venganza Inc. Bioassay for gene silencing constructs
RU2636614C2 (en) * 2009-05-19 2017-11-24 Вивия Байотек С.Л. Methods for personalized medical testing ex vivo for hematological neoplasms
DE102010044131A1 (en) 2010-11-18 2012-05-24 Bayer Schering Pharma Aktiengesellschaft Substituted sodium 1H-pyrazole-5-olate
WO2012071420A1 (en) * 2010-11-23 2012-05-31 The Trustees Of Columbia University In The City Of New York Enzyme combinations to reduce brain tissue swelling
US20120171120A1 (en) 2010-11-30 2012-07-05 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor
WO2012122295A2 (en) * 2011-03-07 2012-09-13 Ned Biosystems, Inc. Treatment for pancreatic adenocarcinoma and other cancers of epithelial origin
US20120312840A1 (en) * 2011-05-13 2012-12-13 Ayako Hasegawa Container closure system with integral antimicrobial additives
WO2014130648A1 (en) 2013-02-20 2014-08-28 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis
US20160000777A1 (en) * 2013-02-21 2016-01-07 University Of Rochester Methods of using histamine receptor agonists and antagonists
WO2015023830A1 (en) * 2013-08-14 2015-02-19 Stc.Unm Treatment and prevention of stroke and other neurological disorders
MX2016003942A (en) 2013-09-24 2016-10-03 Univ Washington Through Its Center For Commercialization Desmoglein 2 (dsg2) binding proteins and uses therefor.
WO2015168671A1 (en) * 2014-05-02 2015-11-05 Arthrodynamic Technologies, Animal Health Division, Inc. Glycosaminoglycan composition and method of use for kidney stone removal
EP3344064A4 (en) * 2015-03-24 2019-08-07 Advanced Aesthetic Technologies, Inc. Kits and methods of using enzymes to modify polysaccharide fillers and delivery systems
WO2018026784A1 (en) * 2016-08-01 2018-02-08 University Of Georgia Research Foundation, Inc. In situ cell delivery using reconstituted photopolymerized chondroitin sulfate glycosaminoglycan hydrogel matrices
WO2021253008A1 (en) * 2020-06-12 2021-12-16 Ihp Therapeutics Inc. Partially desulfated heparin for treating coronaviral infections
CN116113831A (en) * 2020-06-23 2023-05-12 布里格姆妇女医院 Single molecule analysis for ultrasensitive detection of biomolecules

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004745A1 (en) * 1989-09-27 1991-04-18 Athena Neurosciences, Inc. Compositions for cell adhesion inhibition and methods of use
WO1996037196A1 (en) * 1995-05-24 1996-11-28 University Of Maryland At Baltimore Oral dosage composition for intestinal delivery and method of use of the same
WO1998014186A1 (en) * 1996-09-30 1998-04-09 Eisai Co., Limited Substances and their uses
WO1998030211A1 (en) * 1997-01-09 1998-07-16 University Of Maryland, Baltimore Dosage composition for nasal delivery and method of use of the same
WO1998037096A1 (en) * 1997-02-20 1998-08-27 University Of Maryland, Baltimore Zonula occludens toxin receptors
WO1999015649A2 (en) * 1997-09-24 1999-04-01 Elan Corporation, Plc Composition and method for enhancing paracellular transport across cell layers
WO2003098991A2 (en) * 2003-01-10 2003-12-04 Centro De Investigacion Y De Estudios Avanzados Del Instituto Politecnico Nacional Employment of rotavirus proteins, derived proteins and peptides for the modulation of tissue permeability

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262325A (en) 1991-04-04 1993-11-16 Ibex Technologies, Inc. Method for the enzymatic neutralization of heparin
US5411733A (en) * 1992-04-27 1995-05-02 Hozumi; Toyoharu Antiviral agent containing crude drug
GB9323884D0 (en) 1993-11-19 1994-01-05 Eisai London Res Lab Ltd Physiological modulation
US6165976A (en) 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
US6217863B1 (en) 1995-10-30 2001-04-17 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from heparinase I
WO1997033605A1 (en) 1996-03-15 1997-09-18 Yale University Human occludin, its uses and enhancement of drug absorption using occludin inhibitors
CA2341412A1 (en) 1998-08-27 2000-03-09 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase i and ii
US7056504B1 (en) 1998-08-27 2006-06-06 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II
US6756356B2 (en) 1998-11-03 2004-06-29 Adherex Technologies, Inc. Compounds and methods for modulating claudin-mediated functions
NL1011680C2 (en) 1999-03-26 2000-09-27 Nutricia Nv Food compositions containing lightly negatively charged, non-digestible polysaccharides and use thereof to reduce transport through tight junctions.
CA2643162C (en) 1999-04-23 2018-01-02 Massachusetts Institute Of Technology Polymer identification, compositional analysis and sequencing, based on property comparison
WO2001066772A2 (en) 2000-03-08 2001-09-13 Massachusetts Institute Of Technology Heparinase iii and uses thereof
WO2002023190A2 (en) 2000-09-12 2002-03-21 Massachusetts Institute Of Technology Methods and products related to low molecular weight heparin
JP2004523479A (en) 2000-10-18 2004-08-05 マサチューセッツ　インスティテュート　オブ　テクノロジー Methods and products for pulmonary delivery of polysaccharides
CA2441986A1 (en) 2001-03-27 2002-10-03 Massachusetts Institute Of Technology Methods and products related to fgf dimerization
EP1435925A2 (en) * 2001-10-17 2004-07-14 University of Wales College of Medicine Gap junctions and edhf
CA2484604C (en) 2002-05-03 2011-08-02 Massachusetts Institute Of Technology .delta. 4,5 glycuronidase and uses thereof
WO2004055491A2 (en) 2002-05-20 2004-07-01 Massachusetts Institute Of Technology Novel method for sequence determination using nmr
WO2003102160A2 (en) 2002-06-03 2003-12-11 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from chondroitinase b
JP4606712B2 (en) 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー 2-O sulfatase compositions and related methods
WO2005032483A2 (en) * 2003-10-01 2005-04-14 Momenta Pharmaceuticals, Inc. Polysaccharides for pulmonary delivery of active agents
CA2558984A1 (en) 2004-03-10 2005-09-22 Massachusetts Institute Of Technology Recombinant chondroitinase abc i and uses thereof
US20060127950A1 (en) 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
WO2005110438A2 (en) 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the intracellular delivery of polysaccharides
US20060057638A1 (en) 2004-04-15 2006-03-16 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US8529889B2 (en) 2004-06-29 2013-09-10 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
WO2006083328A2 (en) 2004-09-15 2006-08-10 Massachusetts Institute Of Technology Biologically active surfaces and methods of their use
JP2008526258A (en) 2005-01-12 2008-07-24 マサチューセッツ・インスティテュート・オブ・テクノロジー Methods and compositions relating to modulating the extracellular stem cell environment
WO2006089206A2 (en) 2005-02-16 2006-08-24 Massachusetts Institute Of Technology Methods to enhance carbon monoxide dehydrogenase activity and uses thereof
US20090105463A1 (en) 2005-03-29 2009-04-23 Massachusetts Institute Of Technology Compositions of and Methods of Using Oversulfated Glycosaminoglycans
WO2006105315A2 (en) 2005-03-29 2006-10-05 Massachusetts Institute Of Technology Compositions and methods for regulating inflammatory responses
WO2007120478A2 (en) 2006-04-03 2007-10-25 Massachusetts Institute Of Technology Glycomic patterns for the detection of disease
WO2008085912A1 (en) 2007-01-05 2008-07-17 Massachusetts Institute Of Technology Compositions of and methods of using sulfatases from flavobacterium heparinum

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004745A1 (en) * 1989-09-27 1991-04-18 Athena Neurosciences, Inc. Compositions for cell adhesion inhibition and methods of use
WO1996037196A1 (en) * 1995-05-24 1996-11-28 University Of Maryland At Baltimore Oral dosage composition for intestinal delivery and method of use of the same
WO1998014186A1 (en) * 1996-09-30 1998-04-09 Eisai Co., Limited Substances and their uses
WO1998030211A1 (en) * 1997-01-09 1998-07-16 University Of Maryland, Baltimore Dosage composition for nasal delivery and method of use of the same
WO1998037096A1 (en) * 1997-02-20 1998-08-27 University Of Maryland, Baltimore Zonula occludens toxin receptors
WO1999015649A2 (en) * 1997-09-24 1999-04-01 Elan Corporation, Plc Composition and method for enhancing paracellular transport across cell layers
WO2003098991A2 (en) * 2003-01-10 2003-12-04 Centro De Investigacion Y De Estudios Avanzados Del Instituto Politecnico Nacional Employment of rotavirus proteins, derived proteins and peptides for the modulation of tissue permeability

Also Published As

Publication number Publication date
CA2614068A1 (en) 2006-08-24
US8529889B2 (en) 2013-09-10
US20060067927A1 (en) 2006-03-30
EP1768687A2 (en) 2007-04-04
WO2006088491A2 (en) 2006-08-24

Similar Documents

Publication Publication Date Title
WO2006088491A3 (en) Methods and compositions related to the modulation of intercellular junctions
WO2005110438A3 (en) Methods and products related to the intracellular delivery of polysaccharides
WO2006069998A3 (en) Glycopyrrolate in cosmetic preparations
WO2008001240A3 (en) Transdermal delivery of oleocanthal for relief of inflammation
WO2010002586A3 (en) Topical compositions comprising isonicotinamide
HK1105587A1 (en) Compositions and their uses for lysosomal enzyme deficiencies
WO2007077562A3 (en) Antiseptic compositions and methods of using same
WO2007070483A3 (en) Micrornas that regulate muscle cell proliferation and differentiation
MY148869A (en) Methods for reducing the viscosity of treatment fluids comprising diutan
TW200609888A (en) Liquid crystal composition for bistable liquid crystal devices
WO2009099719A3 (en) Compositions and methods for the treatment of tumor of hematopoietic origin
UA88464C2 (en) Method of topical methadone administration providing systemic effect
WO2007103719A3 (en) MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
WO2009055568A3 (en) Liposomal vancomycin formulations
TW200744639A (en) Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
WO2007075895A3 (en) Heterocyclic derivatives as modulators of ion channels
WO2010129819A3 (en) Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
EP1951290A4 (en) Agent for use in the case of fructose intolerance
WO2004080343A3 (en) Compositions and methods for use of alginate dural sealants
TW200728295A (en) Benzochromene derivatives
TW200731965A (en) Topical pain relief compositions of N,2,3-trimethyl-2-isopropylbutamide and methods for using the same
WO2003070905A3 (en) Electroporation methods for introducing bioactive agents into cells
WO2006130493A8 (en) Heterocycles useful as modulators of ion channels
ITMI20051417A1 (en) TOPIC FORMULATION IN THE FORM OF GEL CONTAINING AS ACTIVE CYCLOVIT AND LIDOCAINE INGREDIENTS
WO2004073686A3 (en) Menthol solutions of drugs

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005857486

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005857486

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2614068

Country of ref document: CA